MNMasanari Niwa

Masanari Niwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masanari Niwa has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Torii

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications
  • Dai Okazaki

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications
  • Natsuo Tomita

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications
  • Nozomi Kita

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications
  • Seiya Takano

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications
  • Taiki Takaoka

    Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601

    4 shared publications

Latest Publications

  • Open Access

    Relationship between rectal bleeding and radiation delivery time in intensity-modulated radiotherapy for localized prostate cancer: a preliminary study

    by Nozomi Kita, Natsuo Tomita, Taiki Takaoka, Dai Okazaki, Masanari Niwa, Akira Torii, Seiya Takano, Masanosuke Oguri, Hikaru Tsuzuki, Machiko Ukai, et al.

    The present study investigated the relationship between late grade ≥ 2 rectal bleeding and radiation delivery time in intensity-modulated radiotherapy (IMRT) for localized prostate cancer. We analyzed patients with localized prostate cancer treated with IMRT at our institution between July 2012 and February 2018, including only those treated with 74.8 Gy in 34 fractions (i.e. a fraction dose of 2.2 Gy). To evaluate the relationship between risk factors and late grade ≥ 2 rectal bleeding, we performed univariate analyses using the Gray test and the Fine-Gray model, and multivariate analysis using the Fine-Gray model. Additionally, propensity score matching was performed to adjust for confounding factors. A total of 142 cases were analyzed. The median follow-up period was 83 months. The 7-year cumulative incidence of late grade ≥ 2 rectal bleeding for the entire cohort was 5.7%. The group with shorter delivery time (≤150 s) had a significantly lower 7-year cumulative incidence of late grade ≥ 2 rectal bleeding compared to the group with longer delivery time (>150 s) (1.5% vs. 9.7%, P = 0.036). Multivariate analysis showed a trend toward an association between longer delivery time and increased late grade ≥ 2 rectal bleeding (hazard ratio 6.1, 95% confidence interval 0.78–48, P = 0.085). In the propensity score-matched cohort, the shorter delivery time group showed a significantly lower incidence of late grade ≥ 2 rectal bleeding (0% vs. 11.1%, P = 0.024). In IMRT for localized prostate cancer, shorter radiation delivery time may reduce the incidence of late grade ≥ 2 rectal bleeding.

  • Impact of intensity-modulated radiotherapy on survival and pulmonary toxicities for localized esophageal squamous cell carcinoma

    by Akira Torii, Natsuo Tomita, Taiki Takaoka, Tatsuya Sato, Takuhito Kondo, Dai Okazaki, Masanari Niwa, Nozomi Kita, Seiya Takano, Masanosuke Oguri, et al.

    Objective: Definitive chemoradiotherapy (CRT) is a treatment strategy for localized esophageal squamous cell carcinoma (ESCC). Herein, we aimed to evaluate clinical outcomes of definitive CRT for ESCC. Methods: We reviewed 127 patients who received definitive CRT for localized ESCC at our institution between January 2004 and December 2022. All patients received elective nodal irradiation with concurrent chemotherapy, primarily comprising cisplatin and 5-fluorouracil, during radiotherapy. Seventeen patients (13%) received intensity-modulated radiation therapy (IMRT) only, and 16 patients (13%) were treated with IMRT as a boost. The median total dose was 61.4 Gy. Approximately 80% of the patients had clinical stage III or higher disease. We analyzed overall survival (OS), progression-free survival (PFS), locoregional recurrence rate (LRR), prognostic factors, and adverse events. Results: The median follow-up period was 13 months for all patients and 22 months for survivors. The 2-year OS, PFS, and LRR were 40.4%, 27.1%, and 30.8%, respectively. The overall complete response rate was 40.2%. On multivariate analysis, clinical stage 0–III (non-T4) (P < .001) and the use of IMRT (P = .034) were significantly associated with better OS. Pulmonary toxicity was significantly lower in the IMRT group (P = .049). Conclusions: IMRT for localized ESCC may improve prognosis and reduce pulmonary toxicity.

  • Optimizing radiation therapy for merkel cell carcinoma: evaluating prognostic factors and treatment outcomes

    by Minori Niwa, Masanari Niwa, Natsuo Tomita, Hiromichi Ishiyama, Ayaka Uchida, Yukihiko Oshima, Hirota Takano, Masayuki Matsuo, Mayu Kuno, Akifumi Miyakawa, et al.

    Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer. Surgery and radiation therapy (RT) are common treatment options; however, an optimal RT strategy has yet to be established. Therefore, the present study examined the outcomes of MCC patients treated with RT, with the aim of elucidating current RT practices and identifying prognostic factors for RT optimization. This was a retrospective analysis of 32 non-metastatic MCC patients treated with RT. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method. The Log-rank test was used to examine the effect of each factor on outcomes. Median age was 80 years, with a median follow-up period of 26 months. The median dose was 52 Gy in 26 fractions and combined with surgery in 23 patients. Two-year LC, PFS, and OS rates were 94, 61, and 74%, respectively. The Log-rank test showed that tumor size ≥ 5 cm was associated with worse LC (p = 0.03). Male sex and the absence of surgery correlated with worse PFS (p = 0.047 and 0.023, respectively). Performance status ≥ 2, the absence of surgery, and RT margin < 3 cm correlated with worse OS (p = 0.006, 0.02, and 0.02, respectively). RT dose, intensity-modulated RT, and elective nodal irradiation were not associated with any outcomes in this population. RT achieved high local control; however, the metastasis rates were high. A wide RT margin and the combination of RT with surgery may improve the outcomes of MCC patients.

  • Open Access

    Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses

    by Seiya Takano, Natsuo Tomita, Taiki Takaoka, Masanari Niwa, Akira Torii, Nozomi Kita, Dai Okazaki, Kaoru Uchiyama, Mikiko Nakanishi-Imai, Shiho Ayakawa, et al.

    To evaluate the impact of daily fraction doses on late genitourinary (GU) toxicity after salvage radiotherapy (SRT) for prostate cancer. This multi-institutional retrospective study included 212 patients who underwent SRT between 2008 and 2018. All patients received image-guided intensity-modulated SRT at a median dose of 67.2 Gy in 1.8–2.3 Gy/fraction. The cumulative rates of late grade ≥2 GU and gastrointestinal (GI) toxicities were compared using Gray’s test, stratified by the ≤2.0 Gy/fraction (n = 137) and ≥2.1 Gy/fraction groups (n = 75), followed by multivariate analyses. The total dose was represented as an equivalent dose in 2-Gy fractions (EQD2) with α/β = 3 Gy. After a median follow-up of 63 months, the cumulative rates of 5-year late grade ≥2 GU and GI toxicities were 14 and 2.5%, respectively. The cumulative rates of 5-year late grade ≥2 GU toxicity in the ≥2.1 Gy/fraction and ≤2.0 Gy/fraction groups were 22 and 10%, respectively (p = 0.020). In the multivariate analysis, ≥2.1 Gy/fraction was still associated with an increased risk of late grade ≥2 GU toxicity (hazard ratio, 2.37; 95% confidence interval, 1.12–4.99; p = 0.023), while the total dose was not significant. The present results showed that ≥2.1 Gy/fraction resulted in a higher incidence of late grade ≥2 GU toxicity in SRT. The impact of fraction doses on late GU toxicity after SRT remains unknown. The results suggest that higher fraction doses may increase the risk of late GU toxicity in SRT.


  • Open Access

    Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer

    by Nozomi Kita, Natsuo Tomita, Taiki Takaoka, Dai Okazaki, Masanari Niwa, Akira Torii, Seiya Takano, Yuji Mekata, Akio Niimi, Akio Hiwatashi